Neuromyelitis Optica Spectrum Disorder
📧 Sign up to get email alerts when something new happens for Neuromyelitis Optica Spectrum Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
This clinical trial update indicates that a study evaluating the safety of Ravulizumab (Ultomiris) in pregnant and postpartum individuals is…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 3]
This Phase 3 clinical trial update outlines a study evaluating the pharmacokinetics, efficacy, safety, tolerability, and pharmacodynamics of…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. [Phase 1]
Phase 1 clinical trial update assessing the safety and pharmacodynamics of QH103 cell injections in relapsed/refractory antibody-mediated ne…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Apparently Stable Patients
A clinical trial aiming to assess disease activity in apparently stable patients with neuromyelitis optica spectrum disorder to anticipate i…
-
FDA approval · 2026-03-26FDA Approved: BKEMV — Supplemental Application (Amgen Inc)
FDA approved a supplemental application for BKEMV (eculizumab-aeeB) from Amgen.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD [Phase 4]
A Phase 4 clinical trial comparing Rituximab with Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in neuromyelitis optica spectrum d…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study [Phase 4]
This is a multicenter prospective real-world Phase 4 trial evaluating therapy during the acute phase of neuromyelitis optica spectrum disord…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia
AstraZeneca-sponsored epidemiological study on treatment approaches for AQP4-IgG positive neuromyelitis optica spectrum disorder in Russia h…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder [Phase 4]
Phase 4 trial update shows Modified Zipper Therapy for AQP4-IgG positive Neuromyeltis Optica Spectrum Disorder is currently recruiting.
-
EMA approval · 2026-02-16EMA Authorised: Enspryng (satralizumab) — Roche Registration GmbH
The EU authorised Enspryng (satralizumab) by Roche Registration GmbH for neuromyelitis optica spectrum disorder (orphan medicine).
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases [EARLY_Phase 1]
This document reports an early-phase (Phase 1) clinical trial of QT-019C UCAR T-cell therapy targeting CD19 and BCMA in relapsed/refractory …
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Clinical trial registry update describing AQP4-positive NMOSD patients treated with Alexion C5 inhibitor therapies; the registry is currentl…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
CorEvitas is conducting the SPHERES registry for Neuromyelitis Optica Spectrum Disorder and is enrolling participants by invitation to colle…
-
CLINICAL_TRIALS withdrawal · 2026-02-03Clinical Trial Update: A Study of RD06-04 in Patients With Active Autoimmune Diseases [EARLY_Phase 1]
A early Phase 1 study of RD06-04 in active autoimmune diseases has been withdrawn.
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases [EARLY_Phase 1]
Early-phase clinical study of a targeted CD19/BCMA CAR-T therapy for autoimmune diseases is recruiting, including systemic lupus erythematos…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Ofatumumab in AQP4-IgG Seropositive NMOSD [Phase 1, Phase 2]
This document reports a Phase 1/Phase 2 clinical trial evaluating ofatumumab in AQP4-IgG seropositive NMOSD, with recruitment underway.
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD) [NA]
A clinical trial is recruiting to assess the efficacy and safety of transcranial temporal interference stimulation (tTIS) for treating neuro…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
This observational safety study is recruiting to monitor outcomes in women with neuromyelitis optica spectrum disorder who were exposed to U…
-
CLINICAL_TRIALS other · 2026-01-21Clinical Trial Update: Tongji NADs Cohort
Tongji Hospital has announced a NADs cohort trial covering multiple autoimmune neurological diseases including multiple sclerosis and relate…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy [Phase 1]
This is a Phase 1 clinical trial evaluating the safety and feasibility of C-CAR168 for CNS autoimmune diseases. The study is not yet recruit…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
The longitudinal CONQUER study is a long-term clinical trial examining rare neuroimmunologic disorders, including Neuromyelitis Optica and r…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: French Registry for Monitoring Pregnancies for Multiple Sclerosis
A French registry is being established to monitor pregnancies in people with multiple sclerosis and related demyelinating disorders (NMOSD a…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder
A clinical trial update from Assiut University describes a study comparing multiple sclerosis and neuromyelitis optica spectrum disorder, wi…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder [NA]
Clinical trial update on MR-C-014 for neuromyelitis optica spectrum disorder, focusing on acceptability and safety, with enrollment by invit…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases [EARLY_Phase 1]
A Phase 1 trial evaluating a universal CAR T-cell therapy targeting CD19 and BCMA in relapsed/refractory neurological autoimmune diseases, w…